Merck bets on Asia growth with $338m Korea investment

German science and technology giant Merck is betting big on Korea as a manufacturing hub for Asia's booming biopharmaceutical industry, investing 300 million euros ($338 million) in a new production center in Daejeon. The facility, Merck's largest life science investment in Asia-Pacific to date, is central to its "i…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.